Bristol Myers Squibb Co Subsidiaries: 222 by Jurisdiction (BMY) | Sharpnel
BRISTOL MYERS SQUIBB CO (BMY)
NYSE, NYSE · Common Stock · Pharmaceutical Preparations
One email a week from me: what it filed, which 13F holders added or cut, where its scores stand. Free.
American pharmaceutical company
Corporate structure
222 entities across 47 jurisdictions, 6 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-11 — see the exhibit.
Which other public companies file entities in the same places:
Subsidiaries of BRISTOL MYERS SQUIBB CO as disclosed in its SEC filing
Entity
Jurisdiction
Note
BC ULC
Canada
seventy bio, Inc
United States
seventy bio Securities Corporation
United States
Park LLC
United States
Canada Inc.
Canada
Abraxis BioScience Australia Pty Ltd.
Australia
Abraxis BioScience International Holding Company, Inc.
United States
Abraxis BioScience, Inc.
United States
Abraxis BioScience, LLC
United States
AbVitro LLC
United States
Adnexus, a Bristol-Myers Squibb R&D Company
Financial health
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Piotroski F-score
7 / 8
PASSReturn on assets positiveROA 7.8%
PASSOperating cash flow positiveOCF 14.2B
PASSReturn on assets improving-9.7% → 7.8%
PASSCash flow exceeds earningsOCF 14.2B vs NI 7.1B
PASSLong-term debt ratio falling51.4% → 47.6% of assets
How many subsidiaries does BRISTOL MYERS SQUIBB CO file with the SEC?
222, listed in its most recent exhibit 21. They are incorporated across 47 jurisdictions, led by Canada, United States, Australia. 6 of them sit in offshore financial centres. That exhibit is filed with the company's annual report and is the company's own list, not an estimate.
Is BRISTOL MYERS SQUIBB CO financially healthy?
BRISTOL MYERS SQUIBB CO scores 7 out of 8 on the Piotroski F-score. Only 8 of the nine tests could be computed from what it filed; the rest need a prior year it has not reported. Every test and the numbers behind it are shown above, so the arithmetic is checkable rather than something you have to take on trust.
Who are the largest institutional holders of BRISTOL MYERS SQUIBB CO?
Among the managers tracked here, the biggest positions as of the 2026-Q3 13F filings are BlackRock, Inc. (adding), STATE STREET CORP (adding), JPMORGAN CHASE & CO (trimming). Direction is the change in share count against that manager's own previous filing; managers with no prior filing are left out rather than counted as new buyers.
This page is one panel of the terminal
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
United States
AHI Investment, LLC
United States
Allard Labs Acquisition G.P.
United States
Amira Pharmaceuticals, Inc.
United States
Apothecon LLC
United States
Blisa Acquisition G.P.
United States
BMS Bermuda Nominees L.L.C.
United States
BMS Forex Company
United States
BMS Holdings Netherlands Beta B.V.
Netherlands
BMS Ireland Capital Funding Designated Activity Company
Ireland
BMS Korea Holdings L.L.C.
United States
BMS Latin American Nominees L.L.C.
United States
BMS Netherlands Operations B.V.
Netherlands
BMS Pharmaceuticals Germany Holdings B.V.
Netherlands
BMS Pharmaceuticals International Holdings Netherlands B.V.
Netherlands
BMS Pharmaceuticals Korea Holdings B.V.
Netherlands
BMS Pharmaceuticals Mexico Holdings B.V.
Netherlands
BMS Pharmaceuticals Netherlands Holdings B.V.
Netherlands
BMS Real Estate LLC
United States
BMS Spain Investments LLC
United States
BMS Strategic Portfolio Investments Holdings, Inc.
United States
Bristol Laboratories International, S.A.
United States
Bristol Laboratories Medical Information Systems Inc.
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register. These filings span 2026-Q2–2026-Q3 rather than a single quarter, because filers report on their own schedules.